A randomized controlled trial in 3-day post-KT patients with DM or impaired glucose tolerance demonstrated that conventional insulin regimen (subcutaneous isophane or glargine and a part insulin using and blood glucose target 70–180 mg/dL) lowered the incidence of kidney allograft rejection episodes and severe hypoglycemic events when compared to an intensive insulin regimen (intravenous regular insulin using and blood glucose target 70–110 mg/dL). This evidence concerns the gene INS and Impaired glucose tolerance.